BMO Capital raised the firm’s price target on Sarepta (SRPT) to $40 from $25 and keeps a Market Perform rating on the shares. The FDA recommended removal of Elevidys’ hold in ambulatory patients. suggesting that the fatality risk in ambulatory patients is largely independent of non-ambulatory patient risk, the analyst tells investors in a research note. While the financial overhang is partially removed, BMO expects a certain “hesitancy” from physicians and patients for Elevidys treatment in the near-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sell Rating for Sarepta Therapeutics Amidst Uncertainty and Financial Risks
- Sarepta price target raised to $5 from 0c at H.C. Wainwright
- Sarepta initiated with a Market Perform at Bernstein
- Sarepta upgraded to Outperform from Perform at Oppenheimer
- Sarepta upgraded to Neutral from Underweight at JPMorgan